ALK Protein, Mouse, Recombinant (hFc)

Anaplastic lymphoma kinase (ALK) is mostly known for its oncogenic role in several human cancers. Recent evidences clearly indicate new roles of ALK and its genetic aberrations (e.g. gene rearrangements and mutations) in immune evasion, innate and cell-mediated immunity. New ALK-related immunotherapy approaches are demonstrating both preclinical and clinical promises.

Pack Size	Availability	Price/USD
100 μg	5 days	$ 394.00
500 μg	5 days	$ 1,570.00
1 mg	5 days	$ 2,640.00

Pack Size

Availability

Price/USD

Quantity

100 μg

5 days

$ 394.00

500 μg

5 days

$ 1,570.00

1 mg

5 days

$ 2,640.00

Description

Species	Mouse
Expression System	HEK293
Tag	C-hFc
Accession Number	P97793
Synonyms	CD246, Anaplastic lymphoma kinase, ALK tyrosine kinase receptor
Construction	Recombinant Mouse ALK Protein is expressed from HEK293 with hFc tag at the C-Terminus. It contains Ser19-Cys692.[Accession \|P97793]
Protein Purity	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
Molecular Weight	The protein has a predicted MW of 101.11 kDa. Due to glycosylation, the protein migrates to 115-125 kDa based on Tris-Bis PAGE result.

Endotoxin	Less than 1EU per μg by the LAL method.
Formulation	Supplied as 0.22μm filtered solution in PBS, 10% Glycerol (pH 7.4).
Stability & Storage	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Shipping	In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Research Background	Anaplastic lymphoma kinase (ALK) is mostly known for its oncogenic role in several human cancers. Recent evidences clearly indicate new roles of ALK and its genetic aberrations (e.g. gene rearrangements and mutations) in immune evasion, innate and cell-mediated immunity. New ALK-related immunotherapy approaches are demonstrating both preclinical and clinical promises.